Human schistosomiasis

The Lancet

Volumn 383, Issue 9936, 2014, Pages 2253-2264

  Colley, Daniel G ^a   Bustinduy, Amaya L ^b   Secor, W Evan ^c   King, Charles H ^d  

^a UNIVERSITY OF GEORGIA   (United States)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; ARTEMISININ DERIVATIVE; OXAMNIQUINE; PRAZIQUANTEL;

COMORBIDITY; CONFERENCE PAPER; DISEASE CONTROL; DISEASE ELIMINATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; MORBIDITY; PATHOGENESIS; PRIORITY JOURNAL; SCHISTOSOMA; SCHISTOSOMIASIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANIMALS; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; COST OF ILLNESS; FEMALE; HUMANS; IMMUNITY, CELLULAR; INFANT; LIFE CYCLE STAGES; MALE; MIDDLE AGED; PARASITE EGG COUNT; SCHISTOSOMA; SCHISTOSOMIASIS; SCHISTOSOMICIDES; WORLD HEALTH; YOUNG ADULT;

EID: 84903277019     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61949-2     Document Type: Conference Paper

References (150)

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 201 2; 380: 2163-96.
2. Chitsulo L, Loverde P, Engels D. Schistosomiasis. Nat Rev Microbiol 2004; 2: 12-13.
3. Sturrock RF. The schistosomes and their intermediate hosts. In: Mahmoud AAF, ed. Schistosomiasis. London: Imperial College Press, 2001.
4. Lawson JR, Wilson RA. The survival of the cercariae of Schistosoma mansoni in relation to water temperature and glycogen utilization. Parasitology 1980; 81: 337-48.
5. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368: 1106-18.
6. Warren KS, Mahmoud AA, Cummings P, Murphy DJ, Houser HB. Schistosomiasis mansoni in Yemeni in California: duration of infection, presence of disease, therapeutic management. Am J Trop Med Hyg 1974; 23: 902-09.
7. Chabasse D, Bertrand G, Leroux JP, Gauthey N, Hocquet P. Developmental bilharziasis caused by Schistosoma mansoni discovered 37 years after infestation. Bull Soc Pathol Exot 1985; 78: 643-47 (in French).
8. van Oordt BE,van den Heuvel JM,Tielens AG,van den Bergh SG. The energy production of the adult Schistosoma mansoni is for a large part aerobic Mol Biochem Parasitol 1985 16 117-26.
9. Barrett J. Forty years of helminth biochemistry. Parasitology 2009; 136: 1633-42.
10. Huang SC, Freitas TC, Amiel E, et al. Fatty acid oxidation is essential for egg production by the parasitic fl atworm Schistosoma mansoni. PLoS Pathog 2012; 8: e1002996.
11. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, m eta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6: 411-25.
12. Wang LD, Guo JG, Wu XH, et al. China's new strategy to block Schistosoma japonicum transmission: experiences a nd impact beyond schistosomiasis. Trop Med Int Health 2009; 14: 1475-83.
13. Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 2007; 8: 105-16.
14. Zerlotini A, Aguiar ER, Yu F, et al. SchistoDB: an updated genome resource for the three key schistosomes of humans. Nucleic Acids Res 2013; 41: D728-31.
15. Rollinson D, Webster JP, Webster B, Nyakaana S, Jorgensen A, Stothard JR. Genetic diversity of schistosomes and snails: implications for control. Parasitology 2009; 136: 1801-11.
16. Gower CM, Gouvras AN, Lamberton PH, et al. Population genetic structure of Schistosoma mansoni and Schistosoma haematobium from across six sub-Saharan African countries: implications for epidemiology, evolution and control. Acta Trop 2013; 128: 261-74.
17. Huyse T, Webster BL, G eldof S, et al. Bidirectional introgressive hybridization between a cattle and human schistosome species. PLoS Pathog 2009; 5: e1000571.
18. King CH, Keating CE, Muruka JF, et al. Urinary tract morbidity in schistosomiasis haematobia: associations with age and intensity of infection in an endemic area of Coast Province, Kenya. Am J Trop Med Hyg 1988; 39: 361-68.
19. DeStigter KV, King CH, Keating CE, Ouma JH, Siongok TK, Mahmoud AA. Effect of targeted mass treatment on intensity of infection and morbidity in schistosomiasis mansoni: seven-year follow-up of a community in Machakos, Kenya. Trans Assoc Am Physicians 1989; 102: 209-12.
20. Stothard JR, Sousa-Figueiredo JC, Betson M, et al. Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants a nd preschool-aged children. Parasitology 2011; 138: 1593-606.
21. Bustinduy AL, Parraga IM, Thomas CL, et al. Impact of polyparasitic infections on anemia and undernutrition among Kenyan children living in a Schistosoma haematobium-endemic area. Am J Trop Med Hyg 2013; 88: 433-40.
22. Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP. Immunopathogenesis of human schistosomiasis. Parasite Immunol 2009; 31: 163-76.
23. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol 2002; 2: 499-511.
24. Fairfax K, Nascimento M, Huang SC, Everts B, Pearce EJ. Th2 responses in schistosomiasis. Semin Immunopathol 2012; 34: 863-71.
25. Peterson WP, Von Lichtenberg F. Studies on granuloma formation. IV. In vivo antigenicity of schistosome egg antigen in lung tissue. J Immunol 1965; 95: 959-65.
26. Ross AG, Vickers D, Olds GR, Shah SM, McManus DP. Katayama syndrome. Lancet Infect Dis 2007; 7: 218-24.
27. Eloi-Santos SM, Novato-Silva E, Maselli VM, Gazzinelli G, Colley DG, Correa-Oliveira R. Idiotypic sensitization in utero of children born to mothers with schistosomiasis or Chagas'disease. J Clin Invest 1989; 84: 1028-31.
28. King CL, Malhotra I, Mungai P, et al. B cell sensitization to helminthic infection develops in utero in humans. J Immunol 1998; 160: 3578-84.
29. Mohamed AR, al Karawi M, Yasawy MI. Schistosomal colonic disease. Gut 1990; 31: 439-42.
30. Cao J, Liu WJ, Xu XY, Zou XP. Endoscopic findings and clinicopathologic characteristics of colonic s chistosomiasis: a report of 46 cases. World J Gastroenterol 2010; 16: 723-27.
31. Colley DG, Garcia AA, Lambertucci JR, et al. Immune responses during human schistosomiasis. XII. Differential re sponsiveness in patients with hepatosplenic disease. Am J Trop Med Hyg 1986; 35: 793-802.
32. Cheever AW. A quantitative post-mortem study of Schistosomiasis mansoni in man. Am J Trop Med Hyg 1968; 17: 38-64.
33. Strauss E. Hepatosplenic schistosomiasis: a model for the study of portal hypertension. Ann Hepatol 2002; 1: 6-11.
34. Richter J, Correia Dacal AR, Vergetti Siqueira JG, et al. Sonographic prediction of variceal bleeding in patients with liver fibrosis due to Schistosoma mansoni. Trop Med Int Health 1998; 3: 728-35.
35. Lambertucci JR, Serufo JC, Gerspacher-Lara R, et al. Schistosoma mansoni: assessment of morbidity before and after control. Acta Trop 2000; 77: 101-09.
36. Gryseels B. Morbidity due to infection with Schistosoma mansoni: an update. Trop Geogr Med 1992; 44: 189-200.
37. Doehring-Schwerdtfeger E, Abdel-Rahim IM, Mohamed-Ali Q, et al. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: evaluation of morbidity. Am J Trop Med Hyg 1990; 42: 581-86.
38. Wamachi AN, Mayadev JS, Mungai PL, et al. Increased ratio of tumor necrosis factor-alpha to interleukin-10 produ ction is associated with Schistosoma haematobium-induced urinary-tract morbidity. J Infect Dis 2004; 190: 2020-30.
39. Khalaf I, Shokeir A, Shalaby M. Urologic complications of genitourinary schistosomiasis. World J Urol 2012; 30: 31-38.
40. Schwartz DA. Helminths in the induction of cancer II. Schistosoma haematobium and bladder cancer. Trop Geogr Med 1981; 33: 1-7.
41. Kjetland EF, Leutscher PD, Ndhlovu PD. A review of female genital schistosomiasis. Trends Parasitol 2012; 28: 58-65.
42. Jourdan PM, Randrianasolo BS, Feldmeier H, et al. Pathologic mucosal blood vessels in active female genital schistosomiasis: new aspects of a neglected tropical disease. Int J Gynecol Pathol 2013; 32: 137-40.
43. Kjetland EF, Ndhlovu PD, Gomo E, et al. Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS 2006; 20: 593-600.
44. Leutscher P, Ramarokoto CE, Reimert C, Feldmeier H, Esterre P, Vennervald BJ. Community-based study of genital schistosomiasis in men from Madagascar. Lancet 2000; 355: 117-18.
45. Leutscher PD, Host E, Reimert CM. Semen quality in Schistosoma haematobium infected men in Madagascar. Acta Trop 2009; 109: 41-44.
46. King CH, Dangerfield-Cha M. The unacknowledged impact of chronic schistosomiasis. Chronic Illn 2008; 4: 65-79.
47. Friedman JF, Kanzaria HK, Acosta LP, et al. Relationship between Schistosoma japonicum and nutritional status among children and young adults in Leyte, the Ph ilippines. Am J Trop Med Hyg 2005; 72: 527-33.
48. Ezeamama AE, Friedman JF, Acosta LP, et al. Helminth infection and cognitive impairment among Filipino children. Am J Trop Med Hyg 2005; 72: 540-48.
49. Bustinduy AL, Thomas CL, Fiutem JJ, et al. Measuring fitness of Kenyan children with polyparasitic infections using the 20-meter shuttle run test as a morbidity metric. PLoS Negl Tro p Dis 2011; 5: e1213.
50. Friedman JF, Kanzaria HK, McGarvey ST. Human schistosomiasis and anemia: the relationship and potential mechanisms. Trends Parasitol 2005; 21: 386-92.
51. Leenstra T, Acosta LP, Langdon GC, et al. Schistosomiasis japonica, anemia, and iron status in children, adolescents, and young adults in Leyte, Philippines 1 Am J Clin Nutr 2006 83 371-79.
52. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of infl ammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-76.
53. Ndamba J, Makaza N, Munjoma M, Gomo E, Kaondera KC. The physical fitness and work performance of agricultural workers infected with Schistosoma mansoni in Zimbabwe. Ann Trop Med Parasitol 1993; 87: 553-61.
54. Jukes MC, Nokes CA, Alcock KJ, et al, and the Partnership for Child Development. Heavy schistosomiasis associated with poor short-term memory and slower reaction times in Tanzanian schoolchildren. Trop M ed Int Health 2002; 7: 104-17.
55. Mupfasoni D, Karibushi B, Koukounari A, et al. Polyparasite helminth infections and their association to anaemia and undernutrition in Northern Rwanda. PLoS Negl Trop Dis 2009; 3: e517.
56. Gurarie D, Wang X, Bustinduy AL, King CH. Modeling the effect of chronic schistosomiasis on childhood development and the potential for catch-up growth with different drug treatment strategies promoted for control of endemi c schistosomiasis. Am J Trop Med Hyg 2011; 84: 773-81.
57. Coutinho HM, Acosta LP, McGarvey ST, et al. Nutritional status improves after treatment of Schistosoma japonicum-infected children and adolescents. J Nutr 2006; 136: 183-88.
58. Ross AG, McManus DP, Farrar J, Hunstman RJ, Gray DJ, Li YS. Neuroschistosomiasis. J Neurol 2012; 259: 22-32.
59. Mbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D, Downs JA. Examining the relationship between urogenital schistosomiasis and HIV infection. PLoS Negl Trop Dis 2011; 5: e1396.
60. Downs JA, van Dam GJ, Changalucha JM, et al. Association of schistosomiasis and HIV infection in Tanzania. Am J Trop Med Hyg 2012; 87: 868-73.
61. Leutscher PD, Pedersen M, Ra harisolo C, et al. Increased prevalence of leukocytes and elevated cytokine levels in semen from Schistosoma haematobium-infected individuals. J Infect Dis 2005; 191: 1639-47.
62. Secor WE, Shah A, Mwinzi PM, Ndenga BA, Watta CO, Karanja DM. Increased density of human immunodeficiency virus type 1 coreceptors CCR5 and CXCR4 on the surfaces of CD4(+) T cells and monocytes of patients with Schistosoma mansoni infection. Infect Immun 2003; 71: 6668-71.
63. Kallestrup P, Zinyama R, Gomo E, et al. Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RN A load. J Infect Dis 2005; 192: 1956-61.
64. Walson J, Singa B, Sangar éL, et al. Empiric deworming to delay HIV disease progression in adults with HIV who are ineligible for initiation of antiret roviral treatment (the HEAT study): a multi-site, randomised trial. Lancet Infect Dis 2012; 12: 925-32.
65. Sokhna C, Le Hesran JY, Mbaye PA, et al. Increase of malaria attacks among children presenting concomitant infection by Schistosoma mansoni in Senegal. Malar J 2004; 3: 43.
66. Wilson S, Vennervald BJ, Dunne DW. Chronic hepatosplenomegaly in African school children: a common but neglect ed morbidity associated with schistosomiasis and malaria. PLoS Negl Trop Dis 2011; 5: e1149.
67. Wilson S, Vennervald BJ, Kadzo H, et al. Health implications of chronic hepatosplenomegaly in Keny an school-aged children chronically exposed to malarial infections and Schistosoma mansoni. Trans R Soc Trop Med Hyg 2010; 104: 110-16.
68. Lyke KE, Dicko A, Dabo A, et al. Association of Schisto soma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. Am J Trop Med Hyg 2005; 73: 1124-30.
69. Briand V, Watier L, LE Hesran JY, Garcia A, Cot M. Coinfection with Plasmodium falciparum and Schistosoma haematobium: protective effect of schistosomiasis on malaria in Senegalese children? Am J Trop Med Hyg 2005; 72: 702-07.
70. Pierrot C, Wilson S, Lallet H, et al. Identification of a novel antigen of Schistosoma mansoni shared with Plasmodium falciparum and evaluation of different cross-reactive antibo dy subclasses induced by human schistosomiasis and malaria. Infect Immun 2006; 74: 3347-54.
71. De Vlas SJ, Engels D, Rabello AL, et al. Validation of a chart to estimate true Schistosoma mansoni prevalences from simple egg counts. Parasitology 1997; 114: 113-21.
72. WHO. The control of schistosomiasis: second report of the WHO Expert Committee. Geneva World Health Organization 1991.
73. WHO. Preventive Chemotherapy. In: Human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. Geneva: World Health Organization; 2006.
74. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 1972; 14: 397-400.
75. ten Hove RJ, Verweij JJ, Vereecken K, Polman K, Dieye L, van Lieshout L. Multiplex real-time PCR for the detection and quantification of Schistosoma mansoni and S. haematobium infection in stool samples collected in northern Senegal. Trans R Soc Trop Med Hy g 2008; 102: 179-85.
76. Ibironke O, Koukounari A, Asaolu S, Moustaki I, Shiff C. Validation of a new test for Schistosoma haematobium based on detection of Dra1 DNA fragments in urine: evaluation t hrough latent class analysis. PLoS Negl Trop Dis 2012; 6: e1464.
77. Wichmann D, Poppert S, Von Thien H, et al. Prospective European-wide multicentre study on a blood based real-time PCR for the diagnosis of acute schistosomiasis. BMC Infect Dis 2013; 13: 55.
78. Tsang VC, Wilkins PP. Immunodiagnosis of schistosomiasis. Immunol Invest 1997; 26: 175-88.
79. Colley DG, Binder S, Campbell C, et al. A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of Schistosoma mansoni. Am J Trop Med Hyg 2013; 88: 426-32.
80. Salem N, Balkman JD, Wang J, et al. In vivo imaging of schistosomes to assess disease burden using positron emission tomography (PET). PLoS Negl Trop Dis 2010; 4.
81. Chen JJ, Shen CM, Ko YW. Analytical study of a microfl udic DNA amplification chip using water cooling effect. Biomed Microdevices 2013; 15: 261-78.
82. Allan F, Dunn AM, Emery AM, et al. Use of sentinel sn ails for the detection of Schistosoma haematobium transmission on Zanzibar and observations on transmission patterns. Acta Trop 2013; 128: 234-40.
83. Hamburger J, Hoff man O, Kariuki HC, et al. Large-scal e, polymerase chain reaction-based surveillance of Schistosoma haematobium DNA in snails from transmission sites in coastal Kenya: a new tool for studying the dynamics of snail infection. Am J Trop Med Hyg 2004; 71: 765-73.
84. Abbasi I, King CH, Muchiri EM, Hamburger J. Detection of Schistosoma mansoni and Schistosoma haematobium DNA by loop-mediated isothermal amplification: identification of infected snails from early prepatency. Am J Tro p Med Hyg 2010; 83: 427-32.
85. King CH, Sturrock RF, Kariuki HC, Hamburger J. Transmission control for schistosomiasis-why it matters now. Trends Parasitol 2006; 22: 575-82.
86. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008; 21: 659-67.
87. Brindley PJ, Sher A. The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. J Immunol 1987; 139: 215-20.
88. Montresor A, Engels D, Chitsulo L, Bundy DA, Brooker S, Savioli L. Development and validation of a 'tablet pole'for the administration of praziquantel in sub-Saharan Africa. Trans R Soc Trop Med Hyg 2001; 95: 542-44.
89. Sousa-Figueiredo JC, Betson M, Stothard JR. Treatment of schistosomiasis in African infants and preschool-aged children: downward extension and biometric optimization of the current praziquantel dose pole. In Health 2012; 4: 95-102.
90. Sousa-Figueiredo JC, Betson M, Atuhaire A, et al. Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis 2012; 6: e186 4.
91. Stothard JR, Sousa-Figueiredo JC, Betson M, Bustinduy A, Reinhard-Rupp J. Schistosomiasis in African infants and preschool children: let them now be treated! Trends Parasitol 2013; 29: 197-205.
92. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Xiao S, Tanner M. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet 2000; 355: 1320-25.
93. Pérez del Villar L, Burguillo FJ, López-Abá n J, Muro A. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One 2012; 7: e45867.
94. Katz N, Rocha RS, de Souza CP, et al. Efficacy of alternating therapy with oxamniquine and praziquantel to treat Schistosoma mansoni in children following failure of first treatment. Am J Tr op Med Hyg 1991; 44: 509-12.
95. Keystone JS. Seizures and electroencephalograph changes associated with oxamniquine therapy. Am J Trop Med Hyg 1978; 27: 360-62.
96. Doen hoff MJ, Kusel JR, Coles GC, Cioli D. Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 2002; 96: 465-69.
97. Danso-Appiah A, De Vlas SJ. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol 2002; 18: 125-29.
98. King CH, Olbrych SK, So on M, Singer ME, Carter J, Colley DG. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl Trop Dis 2011; 5: e1321.
99. Keating JH, Wilson RA, Skelly PJ. No overt cellular infl ammation around intravascular schistosomes in vivo. J Parasitol 2006; 92: 1365-69.
100. Doenhoff MJ, Modha J, Lambertucc i JR, McLaren DJ. The immune dependence of chemotherapy. Parasitol Today 1991; 7: 16-18.
101. Wilson RA. The saga of schistosome migration and attrition. Parasitology 2009; 136: 1581-92.
102. Warren KS. Regulation of the prevalence and intensity of schistosomiasis in man: immunology or ecology? J Infect Dis 1973; 127: 595-609.
103. Fitzsimmons CM, Jones FM, Pinot de Moira A, et al. Progressive cross-reactivity in IgE responses: an explanation for the slow development of human immunity to schistosomiasis? Infect Immun 2012; 80: 4264-70.
104. Mitchell KM, Mutapi F, Savill NJ, Woolhouse ME. Protective immunity to Schistosoma haematobium infection is primarily an anti-fecundity response stimulated by the death of adult worms. Proc Natl Acad Sci USA 2012; 109: 13347-52.
105. Karanja DM, Hightower AW, Colley DG, et al. Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal st udy. Lancet 2002; 360: 592-96.
106. Hsü HF, Hsü SY, Osborne JW. Immunization against Schistosoma japonicum in rhesus monkeys. Nature 1965; 206: 1338-40.
107. Yole DS, Pemberton R, Reid GD, Wilson RA. Protective immunity to Schistosoma mansoni induced in the olive baboon Papio anubis by the irradiated cercaria vaccine. Parasitology 1996; 112: 37-46.
108. Mitchell KM, Mutapi F, Savill NJ, Woolhouse ME. Explaining observed infection and antibody age-profiles in populations with urogenital schistosomiasis. PLoS Comput Biol 2011; 7: e1002237.
109. Walter K, Fulford AJ, McBeath R, et al. Increased human IgE induced by killing Schistosoma mansoni in vivo is associated with pretreatment Th2 cytokine responsiveness to worm antigens. J Immunol 2006; 177: 5490-98.
110. Bourke CD, Nausch N, Rujeni N, et al. Integrated analysis of innate, Th1, Th2, Th17, and regulatory cytokines identifies changes in immune polarisation following treatment of human schistosomiasis. J Infect Dis 2013; 208: 159-69.
111. Reimert CM, Fitzsi mmons CM, Joseph S, et al. Eosinophil activity in Schistosoma mansoni infections in vivo and in vitro in relation to plasma cytokine profile pre-and posttreatment with praziquantel. Clin Vaccine Immunol 2006; 13: 584-93.
112. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008; 21: 225-42.
113. WHO. Preventive Chemotherapy Databank. Geneva: World Health Organization; 2013.
114. Carabin H, Marshall CM, Joseph L, Riley S, Olveda R, McGarvey ST. Estimating the intensity of infection with Schistosoma japonicum in villagers of leyte, Philippines. Part I: a Bayesian cumulative logit model. The schistosomiasis transmission and ecology project (STEP). Am J Trop Med Hyg 2005; 72: 745-53.
115. Savioli L, Hatz C, Dixon H, Kisumku UM, Mott KE. Control of morbi dity due to Schistosoma haematobium on Pemba Island: egg excretion and hematuria as indicators of infection Am J Trop Med Hyg 1990 43 289-95.
116. Shane HL, Verani JR, Abudho B, et al. Evaluation of urine CCA assays for detection of Schistosoma mansoni infection in Western Kenya. PLoS Negl Trop Dis 2011; 5: e951.
117. Giboda M, Bergquist NR. Post-transmission schistosomiasis. Parasitol Today 1999; 15: 307-08.
118. Olson CL, Acosta LP, Hochberg NS, et al. Anemia of infl ammation is related to cognitive impairment among children in Leyte, the Philippines. PLoS Negl Trop Dis 2009 ; 3: e533.
119. Ezeamama AE, McGarvey ST, Hogan J, et al. Treatment for Schistosoma japonicum, reduction of intestinal parasite load, and cognitive test score improvements in school-aged children. PLo S Negl Trop Dis 2012; 6: e1634.
120. Terer CC, Bustinduy AL, Magtanong RV, et al. Evaluation of the health-related quality of life of children in Schistosoma haematobiumendemic communities in Kenya: a cross-sectional study. PLoS Negl Trop Dis 2013; 7: e2106.
121. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes i n endemic schistosomiasis. Lancet 2005; 365: 1561-69.
122. Baker MC, Mathieu E, Fleming FM, et al. Mapping, monitoring, and surveillance of neglected tropical diseases: towards a policy framework. Lancet 2010; 375: 231-38.
123. Pullan RL, Bethony JM, Geiger SM, et al. Human helminth coinfection: analysis of spatial patterns and risk factors in a Brazilian community. PLoS Negl Trop Di s 2008; 2: e352.
124. Simoonga C, Utzinger J, Brooker S, et al. Remote sensing, geographical information system and spatial analysis for schistosomiasis epidemiology and ecology in Africa. Parasit ology 2009; 136: 1683-93.
125. Gutman J, Fagbemi A, Alphonsus K, Eigege A, Miri ES, Richards FO Jr. Missed treatment opportunities for schistosomiasis mansoni, in an active programme for the treatment of urinary schistosomiasis in Plateau and Nasarawa states, Nigeria. Ann Trop Med Parasitol 2008; 102: 335-46.
126. Pelletreau S, Nyaku M, Dembele M, et al. The field-testing of a novel integrated mapping protocol for neglected tropical diseases. PLoS Negl Trop Dis 2011; 5: e1380.
127. Richards FO Jr., Eigege A, Miri ES, Jinadu MY, Hopkins DR. Integration of mass drug administration programmes in Nigeria: The challenge of sch istosomiasis. Bull World Health Organ 2006; 84: 673-76.
128. Sturrock HJ, Gething PW, Clements AC, Brooker S. Optimal survey designs for targeting chemotherapy against soil-transmitted helminths: effect of spatial heterogeneity and cost-efficiency of sampling. Am J Trop Me d Hyg 2010; 82: 1079-87.
129. WHO. Idenitification of high risk communities for schistosomiasis in Africa: a multicountry study. Geneva: World Health Organization, 1995.
130. Proietti FA, Antunes CM. Sensitivity, specificity and positive predictive value of selected clinical signs and symptoms associated with schistosomiasis mansoni. Int J Epidemiol 1989; 18: 680-83.
131. Betson M, Sou sa-Figueiredo JC, Kabatereine NB, Stothard JR. Use of fecal occult blood tests as epidemiologic indicators of morbidity associated with intestinal schistosomiasis during preventive chemotherapy in young children. Am J Trop Med Hyg 2 012; 87: 694-700.
132. Olives C, Valadez JJ, Brooker SJ, Pagano M. Multiple category-lot quality assurance sampling: a new classification system with application to schistosomiasis control. PLoS Negl Trop Dis 2012; 6: e1806.
133. WHO. The control of schistosomiasis: report of a WHO Expert Committee. Geneva: World Health Organization, 1985.
134. Fenwick A, Savioli L, Engels D, Robe rt Bergquist N, Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 2003; 19: 509-15.
135. Utzinger J, Keiser J. Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother 2004; 5: 263-85.
136. WHO. Report of a meeting to review the results of studies on the treatment of schistosomiasis in preschool-aged children. Geneva World Health Organization 2010.
137. London declaration on neglected tropical diseases. http://www.who. int/neglected-diseases/London-Declaration-NTDs.pdf (accessed Jan 31, 2014).
138. Rollinson D, Knopp S, Levitz S, et al. Time to set the agenda for schistosomiasis elimination. Acta Trop 2013; 128: 423-40.
139. Dai JR, Wang W, Liang YS, Li HJ, Guan XH, Zhu YC. A novel molluscicidal formulation of niclosamide. Parasitol Res 2008; 103: 405-12.
140. Oliveira-Filho EC, Paumgar tten FJ. Toxicity of Euphorbia milii latex and niclosamide to snails and nontarget aquatic species. Ecotoxicol Environ Saf 2000; 46: 342-50.
141. Takougang I, Meli J, Wabo PonéJ, Angwafo F 3rd. Community acceptability of the use of low-dose niclosamide (Bayluscide), as a molluscicide in the control of human schistosomiasis in Sahelian Cameroon. Ann Trop Med Parasitol 2007; 101: 479-86.
142. Kenawy R, Rizk S. Polymeric controlled release formulations of niclosamide for control of Biomphalaria alexandrina, the vector snail of schistosomiasis. Macromol Biosci 2004; 4: 119-28.
143. Dawson VK, Schreier TM, Boogaard MA, Spanjers NJ, Gingerich WH. Rapid loss of lampricide from catfish and rainbow trout following routine treatment. J Agric Food Chem 2002; 50: 6780-85.
144. Yasuraoka K, Santo s AT Jr., Blas BL, et al. Schistosomiasis on Bohol Island, Philippines, with special emphasis on the successful discovery of new habitats of the vector snail, Oncomelania quadrasi, and area-wide mollusciciding. Jpn J Exp Med 1989; 59: 149-55.
145. Zaki AA. The effect of systematic application of bayluscide on controlling bilharziasis. East Afr Med J 1971; 48: 218-27.
146. Li YZ, Xing YT, Li HJ, et al. Studies on standardization of methods for screening molluscicides in laboratory IV sensitivity of Oncomelania snails from different months to niclosamide. Zhongguo xue xi chong bing fang zhi za zhi 2012; 24: 35-39 (in Chinese).
147. Jordan P. Schistosomiasis-the St. Lucia project. Cambridge; New York: Cambridge University Press, 1985.
148. Knopp S, Mohammed KA, Ali SM, et al. Study and implementati on of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands) using an integrated multidisciplinary approach. BMC Public Health 2012; 12: 930.
149. 65th World Health Assembly. Elimination of schistosomiasis. http://www.who.int/neglected-diseases/mediacentre/WHA-65.21-Eng.pdf (accessed Jan 31, 2014).
150. WHO. Schistosomiasis Progress Report. 2001-2011 and Strategic Plan 2012-2020. Geneva: World Health Organization, 2012.